Phuturdex › Diseases › Skin neoplasm
Drugs in development · updated 30 October 2026
Skin neoplasm: drugs in development
As of 30 October 2026 there are 49 active clinical trials (recruiting or ongoing, phases I–III) on 50 drugs for skin neoplasm. 14 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| FianlimabREGN3767 | III | 3 | NCT05608291 |
| Alintegimod | I–II | 1 | NCT06362369 |
| IOV-4001 | I–II | 1 | NCT05361174 |
| MDNA11 | I–II | 1 | NCT05086692 |
| OBX-115 | I–II | 1 | NCT06060613 |
| Vidutolimod | II | 1 | NCT07808515 |
| [68Ga]Ga-FAPI-46Gallium Ga 68 FAPi-46 | I | 1 | NCT04459273 |
| DK210 | I | 1 | NCT05704985 |
| KFA115 | I | 1 | NCT05544929 |
| KUP-101A | I | 1 | NCT07600476 |
| MQ719 | I | 1 | NCT05859074 |
| ONM-501 | I | 1 | NCT06022029 |
| XL888 | I | 1 | NCT02721459 |
| NicotinamideNicotinomide | Early I | 1 | NCT05702398 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CemiplimabREGN2810, Libtayo® | III | 13 | NCT06585410 |
| PembrolizumabKEYTRUDA, MK-3475 | II–III | 10 | NCT06947928 |
| NivolumabOpdivo, ONO-4538 | III | 8 | NCT07815574 |
| IpilimumabYERVOY, ipililumab IV | III | 7 | NCT07815574 |
| LifileucelLN-145, Amtagvi® | III | 3 | NCT05727904 |
| BinimetinibMEK162, Mektovi® | III | 2 | NCT04657991 |
| EncorafenibBraftovi® | III | 2 | NCT04657991 |
| PertuzumabPerjeta, Poherdy® | II–III | 1 | NCT05786716 |
| SirolimusRapamycin, Scomara® | III | 1 | NCT05860881 |
| TrastuzumabHerceptin, tratuzumab | II–III | 1 | NCT05786716 |
| AtezolizumabTecentriq, MPDL3280A | II | 2 | NCT04273061 |
| AvelumabBavencio® | II | 2 | NCT03944941 |
| CyclophosphamideCyclophosphamid, Cytoxan | II | 2 | NCT02621021 |
| FludarabineFludara, FLUDARABIN | II | 2 | NCT02621021 |
| AfatinibGilotrif®, Giotrif® | II | 1 | NCT05070403 |
Sorted by most advanced phase and number of active trials. Showing 15 of 36 drugs.
All 50 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Melanoma 352 drugs
- Non-small-cell lung carcinoma 726 drugs
- Head and neck squamous cell carcinoma 321 drugs
- Renal cell carcinoma 228 drugs
- Colorectal neoplasm 534 drugs
- Metastasis 493 drugs
- Neoplasm 671 drugs
- Ovarian neoplasm 411 drugs
- Stomach neoplasm 340 drugs
- Triple-negative breast neoplasm 334 drugs
- Breast neoplasm 593 drugs
- Lung neoplasm 348 drugs
Broader categories
- Skin disease 34 drugs
- Skin and connective tissue diseases 3 drugs
- Neoplasm 671 drugs
- Neuroectodermal tumor 3 drugs
- Germ cell and embryonal neoplasms 35 drugs
- Nerve tissue neoplasm 4 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D012878 “Skin Neoplasms”.